Pursuing Neutrophils: Systematic Scoping Review on Blood-based Biomarkers As Predictors of Treatment Outcomes in Inflammatory Bowel Disease

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2023 Mar 16

PMID 36923488

Authors

Diogo Magalhaes

Laurent Peyrin-Biroulet

Maria Manuela Estevinho

Silvio Danese

Fernando Magro

Affiliations

Soon will be listed here.

Abstract

Background: Long-term management of inflammatory bowel diseases (IBD) is challenging and the identification of reliable predictors for treatment outcomes is an unmet need. Neutrophil-related biomarkers have been mainly studied in the feces, but blood analyses have inherent advantages.

Objective: To review the recent learnings on the ability of blood-based neutrophil-expressed biomarkers to predict treatment outcomes in IBD.

Design: Systematic scoping review.

Data Sources And Methods: We performed a literature search in Pubmed, EMBASE, SCOPUS, Web of Science, ScienceDirect, and Cochrane Central Register of Controlled Trials from inception until May 2022 according to Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. All human studies associating blood-based neutrophil-related compounds with the prediction of disease progression, complication onset, or treatment outcomes were included.

Results: From 1032 retrieved entries, 34 studies were selected, 32 published in 2013 or later. In all, 17 biomarkers from granules, cytoplasm, plasmatic membrane, and plasma were explored. In total, 1850 Crohn's disease (CD) and 1122 ulcerative colitis non-duplicated patients were included. The most mentioned biomarkers were nCD64, serum calprotectin (SC), oncostatin M (OSM), neutrophil elastase-generated calprotectin fragment (CPa9-HNE), and triggering receptor expressed on myeloid cells 1 (TREM1). Six biomarkers showed promising results: OSM, SC, eNAMPT, nCD64, TREM1, and CPa9-HNE. Variable positive signals were found for human neutrophil peptide 1-3, LL-37, S100A12, and neutrophil gelatinase-associated lipocalin. No predictive ability was found for the remaining markers. Sharing a neutrophil compartment did not indicate similar behavior.

Conclusion: Advances in the last decade began to unveil the untapped potential of the readily accessible blood neutrophil-expressed biomarkers, especially nCD64, TREM1, and CPa9-HNE. Current evidence suggests that future research should focus on well-defined subpopulations instead of a one-size-fits-all biomarker.

Registration: https://osf.io/kes9a.

Citing Articles

Discerning Endoscopic Severity of Inflammatory Bowel Disease by Scoping the Peripheral Blood Transcriptome.

Soderman J, Almer S Gastro Hep Adv. 2024; 3(5):618-633.

PMID: 39165421 PMC: 11330933. DOI: 10.1016/j.gastha.2024.02.009.

Current Approaches for Monitoring of Patients with Inflammatory Bowel Diseases: A Narrative Review.

Vitello A, Maida M, Shahini E, Macaluso F, Orlando A, Grova M J Clin Med. 2024; 13(4).

PMID: 38398321 PMC: 10888591. DOI: 10.3390/jcm13041008.

Location-based prediction model for Crohn's disease regarding a novel serological marker, anti-chitinase 3-like 1 autoantibodies.

Sipeki N, Kovats P, Deutschmann C, Schierack P, Roggenbuck D, Papp M World J Gastroenterol. 2023; 29(42):5728-5750.

PMID: 38075846 PMC: 10701337. DOI: 10.3748/wjg.v29.i42.5728.

Adipokines in pulmonary hypertension: angels or demons?.

Jia Q, Ouyang Y, Yang Y, Yao S, Chen X, Hu Z Heliyon. 2023; 9(11):e22482.

PMID: 38074873 PMC: 10700708. DOI: 10.1016/j.heliyon.2023.e22482.

References

Bolignano D, Della Torre A, Lacquaniti A, Costantino G, Fries W, Buemi M . Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab. J Investig Med. 2010; 58(3):569-71. DOI: 10.231/JIM.0b013e3181ccc20c. View

Xiong Y, Mizuno T, Colman R, Hyams J, Noe J, Boyle B . Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Clin Pharmacol Ther. 2020; 109(6):1639-1647. PMC: 8159860. DOI: 10.1002/cpt.2148. View

West N, Hegazy A, Owens B, Bullers S, Linggi B, Buonocore S . Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017; 23(5):579-589. PMC: 5420447. DOI: 10.1038/nm.4307. View

Tricco A, Lillie E, Zarin W, OBrien K, Colquhoun H, Levac D . PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018; 169(7):467-473. DOI: 10.7326/M18-0850. View

Matusiewicz M, Neubauer K, Mierzchala-Pasierb M, Gamian A, Krzystek-Korpacka M . Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases. Dis Markers. 2014; 2014:643645. PMC: 3988740. DOI: 10.1155/2014/643645. View

Tajra J, Calegaro J, de Paula A, Bachour D, Silveira D, Lozi M . Correlation and concordance measures between clinical, endoscopic and histological scores activity in Crohn's disease under treatment. Scand J Gastroenterol. 2019; 54(4):441-445. DOI: 10.1080/00365521.2019.1596305. View

Vernia F, Viscido A, Ruscio M, Stefanelli G, Valvano M, Latella G . Fecal Lactoferrin and Other Putative Fecal Biomarkers in Crohn's Disease: Do They Still Have a Potential Clinical Role?. Digestion. 2021; 102(6):833-844. DOI: 10.1159/000518419. View

Neubauer K, Bednarz-Misa I, Walecka-Zacharska E, Wierzbicki J, Agrawal A, Gamian A . Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia. Int J Mol Sci. 2019; 20(1). PMC: 6337260. DOI: 10.3390/ijms20010166. View

Marlicz W, Skonieczna-Zydecka K, Dabos K, Loniewski I, Koulaouzidis A . Emerging concepts in non-invasive monitoring of Crohn's disease. Therap Adv Gastroenterol. 2018; 11:1756284818769076. PMC: 5912292. DOI: 10.1177/1756284818769076. View

10.

Colombo G, Clemente N, Zito A, Bracci C, Colombo F, Sangaletti S . Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. J Mol Med (Berl). 2020; 98(4):595-612. DOI: 10.1007/s00109-020-01892-0. View

11.

Lee S, Hwang S, Park S, Yang D, Byeon J, Myung S . Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn's disease in clinical remission: a pilot study. Intest Res. 2022; 20(2):203-212. PMC: 9081997. DOI: 10.5217/ir.2021.00020. View

12.

de Bruyn M, Ringold R, Martens E, Ferrante M, Van Assche G, Opdenakker G . The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor. J Crohns Colitis. 2019; 14(2):176-184. DOI: 10.1093/ecco-jcc/jjz125. View

13.

Gisbert J, Chaparro M . Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. J Crohns Colitis. 2019; 14(5):694-709. DOI: 10.1093/ecco-jcc/jjz195. View

14.

Bertani L, Fornai M, Fornili M, Antonioli L, Benvenuti L, Tapete G . Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther. 2020; 52(2):284-291. DOI: 10.1111/apt.15870. View

15.

Mori A, Mitsuyama K, Sakemi R, Yoshioka S, Fukunaga S, Kuwaki K . Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease. Kurume Med J. 2021; 66(4):209-215. DOI: 10.2739/kurumemedj.MS664009. View

16.

Verstockt B, Verstockt S, Blevi H, Cleynen I, de Bruyn M, Van Assche G . TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?. Gut. 2018; 68(8):1531-1533. DOI: 10.1136/gutjnl-2018-316845. View

17.

Colman R, Tsai Y, Jackson K, Boyle B, Noe J, Hyams J . Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. Inflamm Bowel Dis. 2020; 27(7):1045-1051. PMC: 8205636. DOI: 10.1093/ibd/izaa241. View

18.

Grenier A, Dehoux M, Boutten A, Durand G, Gougerot-Pocidalo M, Chollet-Martin S . Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood. 1999; 93(4):1413-21. View

19.

Tran D, Wang J, Ha C, Ho W, Mattai S, Oikonomopoulos A . Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease. BMC Gastroenterol. 2017; 17(1):63. PMC: 5427565. DOI: 10.1186/s12876-017-0619-4. View

20.

Wagatsuma K, Yokoyama Y, Nakase H . Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel). 2021; 11(12). PMC: 8707558. DOI: 10.3390/life11121375. View